CO5261508A1 - Compuestos bi-basicos como inhibidores de triptasa, procedimiento para su preparacion y su utilizacion como medicamentos - Google Patents

Compuestos bi-basicos como inhibidores de triptasa, procedimiento para su preparacion y su utilizacion como medicamentos

Info

Publication number
CO5261508A1
CO5261508A1 CO00087796A CO00087796A CO5261508A1 CO 5261508 A1 CO5261508 A1 CO 5261508A1 CO 00087796 A CO00087796 A CO 00087796A CO 00087796 A CO00087796 A CO 00087796A CO 5261508 A1 CO5261508 A1 CO 5261508A1
Authority
CO
Colombia
Prior art keywords
basic compounds
triptase
medications
inhibitors
procedure
Prior art date
Application number
CO00087796A
Other languages
English (en)
Inventor
Ralf Anderskewitz
Cristine Braun
Rainer Hamm
Bernd Disse
Hans Michael Jennewein
Georg Speck
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of CO5261508A1 publication Critical patent/CO5261508A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/12—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
    • C07C259/18—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/66—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

1-. Compuestos de la fórmula general (I) B1-Ar1-X1-Ar2-X2-A-X3-Ar3-X4-Ar4-B2 (I)en la queB1 y B2 iguales o diferentes, significan -C(=NR1)-NR1'H, -CH2NH2, -CH2CH2NH2 ó - NH-C(=NH)-NH2;R1 y R1' iguales o diferentes, significan hidrógeno, OH, -COR2 ó -COOR2;R2 significa hidrógeno, alquilo C1-C18, arilo o aril-alquiloC1-C6;Ar1, Ar2, Ar3, Ar4 y aril (o) iguales o diferentes, significan arilo C6-C10, que eventualmente puede estar sustituido de una a cuatro veces con uno o varios radical(es), seleccionado(s) entre el grupo formado por cicloalquilo C3-C10, F, Cl, Br, I, OH, OR3, SR3, NR3R4, COOR3. alquilo C1-C6 y alquenilo C2-C6 y alquinilo C2- C6 pudiendo en los sustituyentes alquilo C1-C6 y alquenilo C2-C6 estar remplazados por F ó OR3 eventualmente uno o varios átomo(s) de hidrógeno, o un anillo de heteroarilo mono- o bi-cíclico de 5-10 miembros, en el que hasta tres átomos de C pueden estar reemplazados por uno o varios heteroátomo(s) seleccionado(s) entre el grupo formado por oxígeno, nitrógeno y azufre, y que eventualmente puede estar sustituido de una a cuatro veces con uno o varios radical(es) seleccionado(s) entre el grupo formado por cicloalquilo C1-C10, F, Cl, Br, I, OH, OR3, SR3, NR3R4, COOR3, alquilo C1-C6, alquenilo C2-C6 y alquinilo C2-C6, pudiendo en los sustituyentes alquilo C1-C6 y alquenilo C2-C6 estar reemplazados por F ó OR3 eventualmente uno o varios átomo(s) de hidrógeno,R3 y R4 iguales o diferentes, significan hidrógeno o un radical seleccionado entre el grupo que consta de alquilo C1-C6 y cicloalquilo C3-C6, en el que eventualmente uno o varios átomo(s) de hidrógeno pueden estar reemplazados por S;X1, X2, X3, y X4 iguales o diferentes, significan un puente seleccionado entre el grupo formado por -(CH2)n, -(CH2)nO-, -(CH2)n-S-, -(CH2)nNR3- y -(CH2)nN R3R4- con n = 1 ó 2;A significa un radical seleccionado entre el grupo formado por alquinelo C2-C16 y alquenileno C2-C16, en el que eventualmente uno o varios átomo(s) de hidrógeno pueden estar reemplazados por uno o varios radical(es) - 2 -seleccionado(s) entre el grupo formado por F, R3, OR3 y COOR3, o alquinileno C2-C16, oA significa -(CH2)l-D-(CH2)m-, pudiendo en los grupos alquileno -(CH2)l- y -(CH2)m- uno o dos átomos de hidrógeno estar reemplazados eventualmente por alquilo C1-C6 y significando D arilo o cicloalquilo C3-C10, en el que eventualmente uno o varios átomo(s) de hidrógeno pueden estar reemplazado(s) por uno o varios radical(es) seleccionado(s) entre el grupo formado por F, R3 y OR3 y l y m, iguales o diferentes, 0, 1, 2, 3, 4, o D -O-, -S- ó -NR3- y l y m, iguales o diferentes, 2, 3 ó 4; oA significa -G1-(CH2)r-G2-, caso de que X2 ó X3 signifiquen -(CH2)n- también -E1-(CH2)r-G1- ó -E1-(CH2)r-E2-, significando r un número 0, 1, 2, 3, 4, 5, ó 6, G1 y G2 iguales o diferentes, un enlace simple o cicloalquilo C3-C10, pero en el caso de que r = 0 o r = 1 G1 y G2 no pueden representar al mismo tiempo un enlace simple; E1 y E2 iguales o diferentes, aza-cicloalquilo C3-C10, que contiene uno o dos átomos de nitrógeno, estando unido por lo menos un átomo de N a X2 ó X3 = (CH2)n,eventualmente en forma de sus racematos, sus enantiómeros, sus diastereoisómeros, tautómeros y sus mezclas, así como eventualmente sus sales por adición de ácidos farmacológicamente inocuas.
CO00087796A 1999-11-18 2000-11-17 Compuestos bi-basicos como inhibidores de triptasa, procedimiento para su preparacion y su utilizacion como medicamentos CO5261508A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19955476A DE19955476A1 (de) 1999-11-18 1999-11-18 Bis-basische Verbindungen als Tryptase-Inhibitoren, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
CO5261508A1 true CO5261508A1 (es) 2003-03-31

Family

ID=7929470

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00087796A CO5261508A1 (es) 1999-11-18 2000-11-17 Compuestos bi-basicos como inhibidores de triptasa, procedimiento para su preparacion y su utilizacion como medicamentos

Country Status (11)

Country Link
EP (1) EP1250317B1 (es)
JP (1) JP2003514792A (es)
AT (1) ATE304527T1 (es)
AU (1) AU2356501A (es)
CA (1) CA2391085C (es)
CO (1) CO5261508A1 (es)
DE (2) DE19955476A1 (es)
ES (1) ES2249321T3 (es)
MX (1) MXPA02004990A (es)
UY (1) UY26435A1 (es)
WO (1) WO2001036374A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001097794A2 (en) * 2000-06-21 2001-12-27 Georgetown University Inhibitors of matriptase for the treatment of cancer
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
US20050227974A9 (en) * 2002-08-01 2005-10-13 Euro-Celtique S.A. Aminoalkyl-substituted aryl compounds and their use as sodium channel blockers
CN110312703B (zh) * 2016-12-22 2022-11-25 威利克斯制药股份有限公司 经脒取代的类似物及其用途
CN110128277B (zh) * 2019-06-06 2021-09-07 中国林业科学研究院林业新技术研究所 cis-对䓝烷-1,8-二仲胺类化合物及其制备方法与除草应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK8599A3 (en) * 1996-07-30 2000-03-13 Arris Pharm Corp Disubstituted cyclic compound, process for its preparation, pharmaceutical composition and method of the treatment of an animal
US6221914B1 (en) * 1997-11-10 2001-04-24 Array Biopharma Inc. Sulfonamide bridging compounds that inhibit tryptase activity
AU2723099A (en) * 1998-02-06 1999-08-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Tryptase inhibitors
EP1060175B1 (de) * 1998-02-06 2004-11-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tryptase-inhibitoren
DE19939463A1 (de) * 1999-08-20 2001-02-22 Boehringer Ingelheim Pharma Aminocarbonyl-substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
EP1250317A2 (de) 2002-10-23
CA2391085A1 (en) 2001-05-25
ES2249321T3 (es) 2006-04-01
DE19955476A1 (de) 2001-05-23
WO2001036374A2 (de) 2001-05-25
JP2003514792A (ja) 2003-04-22
MXPA02004990A (es) 2003-01-28
WO2001036374A3 (de) 2002-04-11
ATE304527T1 (de) 2005-09-15
EP1250317B1 (de) 2005-09-14
CA2391085C (en) 2009-09-29
DE50011185D1 (de) 2005-10-20
AU2356501A (en) 2001-05-30
UY26435A1 (es) 2001-06-29

Similar Documents

Publication Publication Date Title
MY127144A (en) New anticholinergics which may be used as medicaments as well as processes for preparing them
MX9700885A (es) Nuevas heteroariloxazolidinonas.
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
DOP2000000109A (es) Derivados de tiazolilamida
CO4290417A1 (es) Nuevas benzoilguanidinas como medicamentos y su preparacion .
TNSN05007A1 (en) Novel thiophenylglycoside derivatives, methods for production thereof, medicaments comprising said compounds and use thereof.
BR0316375A (pt) Diazinopirimidinas
AP2002002637A0 (en) Novel piperazine
AU2002319814A1 (en) Substituted 1h-dihydropyrazoles, their preparation and use
TR200102800T2 (tr) Yeni bileşikler.
MXPA03000510A (es) Sales estables de acido o-acetilsalicilico con aminoacidos basicos.
WO2001047928A3 (de) Imidazo 1,3,5 triazinone und ihre verwendung
PL364598A1 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
AU7056001A (en) Phenyl-substituted 5,6-dihydropyrone derivatives for use as pesticides and herbicides
YU56302A (sh) Derivati 8,8a-dihidro-indeno/1,2-d/taizola, koji su supstituisani u 8a-položaju,postupak za njihovu proizvodnju i njihova primena kod leka npr.kao anorektičnog sredstva
YU30603A (sh) Derivati premošćenog piperazina
MY133112A (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use
SE0203070D0 (en) Novel compounds
AU2002210425A1 (en) Novel beta-amyloid inhibitors, method for producing the same and the use thereofas medicaments
CO5261508A1 (es) Compuestos bi-basicos como inhibidores de triptasa, procedimiento para su preparacion y su utilizacion como medicamentos
ES2185196T3 (es) Un procedimiento para la preparacion de tetraazamacrociclos.
IL148161A0 (en) Process for the preparation of 2-cyanopyridines
CZ20022240A3 (cs) Mannichovy báze substituovaného 1-a 2-naftolu
ES2163001T3 (es) Nuevos derivados de borneol, procedimiento para su preparacion y su utilizacion farmaceutica.
CA2425368A1 (en) New sulphoxybenzamides

Legal Events

Date Code Title Description
FA Application withdrawn